Some of the biggest antibiotic drug development news this week was provided by a Lancet Infectious Diseases publication, with early results published from the phase two trial of cefiderocol compared with imipenem-cilastatin for the treatment of complicated gram-negative urinary pathogens. Cefiderocol was non-inferior to imipenem-cilastatin in the trial, and the study reports ongoing trials on other infection sites. The story was picked up by multiple media sites, and you can read the original article here.